title: Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer.
abstract: BACKGROUND
  We planned a phase I study of weekly arterial infusion of docetaxel and cisplatin via a superficial temporal artery for recurrent head and neck cancer to determine the optimal dose.
  
  
  METHODS
  The dose of cisplatin was fixed and the dose of docetaxel was escalated from 8 mg/m(2) , with an increase of 2 mg/m(2) per step, to identify the maximum tolerated dose (MTD). In total, 4 courses of weekly chemotherapy were administered.
  
  
  RESULTS
  Twelve patients were recruited to this trial. The MTD of docetaxel was 14 mg/m(2) . At this dose level, dose-limiting toxicity was observed in 2 of 3 patients. One patient experienced grade 3 leukopenia, while the other experienced grade 3 leukopenia. Myelosuppression was the dose-limiting toxicity for this regimen.
  
  
  CONCLUSIONS
  The recommended dose for weekly arterial infusion of docetaxel was identified as 12 mg/m(2) combined with weekly cisplatin at 40 mg/m(2) , with 4 courses of each.
authors.affiliation: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan. tatsuya.nakamura@nifty.com
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakamura
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Fuwa
authors.forename: Kanako
authors.initials: K
authors.lastname: Takayama
authors.forename: Haruo
authors.initials: H
authors.lastname: Inokuchi
authors.forename: Takuya
authors.initials: T
authors.lastname: Tomoda
authors.forename: Akinori
authors.initials: A
authors.lastname: Takada
authors.forename: Chiyoko
authors.initials: C
authors.lastname: Makita
authors.forename: Miho
authors.initials: M
authors.lastname: Shiomi
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Yokouchi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin